New treatments from AstraZeneca and Xcovery/Betta Pharmaceuticals for generalized myasthenia gravis and ALK-positive advanced non-small cell lung cancer, respectively are on track for EU-wide marketing authorization.
New treatments from AstraZeneca and Xcovery/Betta Pharmaceuticals for generalized myasthenia gravis and ALK-positive advanced non-small cell lung cancer, respectively are on track for EU-wide marketing authorization.